The corporate is aiming to launch the product as quickly because the Danish drug maker Novo Nordisk’s patent expires early subsequent 12 months, high firm officers stated.
“The Topic Professional Committee (SEC) below Central Medication Normal Management Group (CDSCO) beneficial grant of permission to fabricate and market semaglutide injection in India. We’re within the technique of getting the ultimate approval and launch the product as quickly because the patent expires within the Indian market (early subsequent 12 months),” stated MV Ramana, chief govt officer, branded markets (India and Rising Markets), after the corporate introduced its second quarter outcomes publish market hours on Friday.
Semaglutide patent in India is ready to run out in March 2026.
“We have to get the approval from the DCGI. Our aspiration is to launch the product as quickly because the patent expires,” he stated.
Nonetheless, the corporate dominated out any advertising partnership with Eli Lilly for its weight reduction molecule tirzepatide. Requested if the corporate was on the lookout for any such collaboration with the US drug maker, “We’re not,” stated Erez Israeli, chief govt officer, Dr Reddy’s Lab.Lilly’s Mounjaro (tirzepatide) is now the top-selling drug within the Indian pharmaceutical market with gross sales worth surging to Rs 112 crore in six months of its launch. Novo Nordisk’s Wegovy (semaglutide), then again, might publish solely Rs 28 crore in 4 months since its launch in June.On Friday, Dr Reddy’s Laboratories reported a 9.8% rise in consolidated revenues year-on-year (YoY) to Rs 8,805 crore, whereas revenue after tax elevated 14% YoY to Rs 1,437crore. EBITDA margin was at 26.7% vs 28.4% in Q2 FY5.
Nonetheless, gross margins contracted by 492 foundation factors YoY to 54.7%, largely attributable to decrease Lenalidomide gross sales, value erosion within the US generics phase and one-time stock provisions linked to discontinued pipeline merchandise.
Progress within the second quarter was pushed by momentum in branded markets and regular contributions from the Nicotine Substitute Remedy (NRT) portfolio, which helped offset the decline in US Lenalidomide gross sales.
On tirzepatide gaining traction over rival semaglutide in India, Ramana is of the view that after the patent expiry, the market will evolve in another way.
The corporate had earlier stated it was betting massive on generic semaglutide and had plans to launch in 87 nations in 2026 – as a future development driver.
“In different markets we’re having lively dialog with the regulators and the hassle will likely be that as and when the patent expires in these nations, we can take the merchandise into the market,” stated Israeli.
Although the corporate didn’t share any specifics of pricing of the generic product, it stated it will likely be aggressive.
“There are different firms that will likely be launching the product and therefore it will likely be a aggressive market. However having stated that, we anticipate a big quantity of unmet want each from the purpose of diabetes and the flexibility to handle weight problems so this market will develop and gamers who’ve management on the worth chain would undoubtedly profit and get a part of the expansion,” stated Ramana.
